MODIFICATION OF D-GALACTOSAMINE-INDUCED LIVER-INJURY IN THE RAT BY SPIRONOLACTONE

被引：1

作者：

MIHAS, AA ^{[1
]}

FOSTER, MM ^{[1
]}

BARNES, S ^{[1
]}

MIHAS, TA ^{[1
]}

HIRSCHOWITZ, BI ^{[1
]}

SPENNEY, JG ^{[1
]}

机构：

[1] VET ADM HOSP, BIRMINGHAM, AL 35233 USA

来源：

PHARMACOLOGY | 1979年 / 18卷 / 05期

关键词：

Bile salts; D-Galactosamine; Hepatic necrosis; Hepatotoxicity; Liver injury; Rat liver; Serum bile salt measurement; Spironolactone;

D O I：

10.1159/000137258

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Spironolactone, a competitive inhibitor of mineralocorticoid effects on the distal tubule of the kidney, has recently been found to have other metabolic effects. In these studies, spironolactone (200 mg/kg intraperitoneally) for 3 days was found to have a marked protective effect against die hepatotoxic effect of D-galactosamine (275 mg/kg) in rats. Further progress in defining the mechanism of protection from D-galactosamine hepatic necrosis by spironolactone will require assessment of effects of spironolactone on uridine nucleotide metabolism. © 1979 S. Karger AG, Basel.

引用

页码：235 / 240

页数：6

共 15 条

[1] DECKER K, 1972, P183
[2] INTERACTIONS OF SPRIONOLACTONE WITH HEPATIC MICROSOMAL DRUG-METABOLIZING ENZYME SYSTEMS
FELLER, DR
GERALD, MC
[J]. BIOCHEMICAL PHARMACOLOGY, 1971, 20 (08) : 1991 - &
[3] FELLER DR, 1971, P SOC EXP BIOL MED, V136, P1347
[4] TRANSAMINASE ACTIVITY IN HUMAN BLOOD
KARMEN, A
WROBLEWSKI, F
LADUE, JS
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (01) : 126 - 133
[5] KOFF RS, 1971, P SOC EXP BIOL MED, V138, P89
[6] KOVACS K, 1969, P SOC EXP BIOL MED, V131, P1350
[7] LIEHR H, 1978, VIRCHOWS ARCH B, V26, P331
[8] SPIRONOLACTONE AND TESTICULAR CYTOCHROME-P-450 - DECREASED TESTOSTERONE FORMATION IN SEVERAL SPECIES AND CHANGES IN HEPATIC DRUG-METABOLISM
MENARD, RH
STRIPP, B
GILLETTE, JR
[J]. ENDOCRINOLOGY, 1974, 94 (06) : 1628 - 1636
[9] MIGUET JP, 1977, GASTROEN CLIN BIOL, V1, P1007
[10] Mihas A A, 1976, Ala J Med Sci, V13, P384

← 1 2 →